Stories have been a catalyst for conversation for centuries. Generations of families are often weaved together by the narrative of a loved one’s past, and by the stories that have shaped our evolution. There is so much to learn through the stories of those who came before us. As a…
The Power of PF Storytelling, and a Plea for Change
People with idiopathic pulmonary fibrosis (IPF) who live in poorer neighborhoods are less likely to receive a lung transplant and have a higher mortality risk, a U.S. single-center study reports. The study’s lead researcher said she was surprised the findings of “neighborhood-level disadvantage” reached significance given the relatively…
I will celebrate my two-year diagnosis anniversary on Dec. 11. On this day, which changed my life forever, I was finally diagnosed with lymphocytic interstitial pneumonia. My head was spinning when I heard these words. What is this illness? I wondered. Is it curable? It must be curable, I…
In 2014, I was living my life without a care in the world. Oh, I had a few health issues, but none that worried me at the time. Therefore, I had scheduled a vacation in Sweden for July. Little did I know I would soon be “Riding the IPF Roller…
Veracyte has presented new data demonstrating the diagnostic performance and utility of its Envisia Genomic Classifier to help distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILDs). The company is now…
While receiving treatment at specialized centers lowers the risk of hospitalization among patients with idiopathic pulmonary fibrosis (IPF), being a former smoker and requiring oxygen therapy are both associated with a higher likelihood of hospitalization. These are some of the findings of multiple studies that Boehringer Ingelheim will…
When someone receives a life-changing diagnosis, it can feel like their world is caving in. A diagnosis changes a person’s landscape, alters their expectations, and obstructs their former worldview. Some people understand what this is like, while others, no matter how hard they try, just don’t get it.
Algernon Pharmaceuticals has announced that its Phase 2 trial of oral NP-120 (ifenprodil) in treating chronic cough associated with idiopathic pulmonary fibrosis (IPF) has reached 50% of its enrollment target. The proof-of-concept and open-label study (NCT04318704), currently underway at four sites in Australia and two in New…
Magnesium lithospermate B, a compound found in a traditional Chinese medicinal herb, eased several features of pulmonary fibrosis (PF) in a mouse model of the disorder. According to investigators, the anti-fibrotic effects of this plant compound were comparable to those of Esbriet (pirfenidone), an approved treatment for…
In a move that refocuses its clinical pipeline, Galapagos is discontinuing the development of GLPG1205, its experimental therapy for idiopathic pulmonary fibrosis (IPF), and advancing its most recent IPF candidate, GLPG4617, into a Phase 2 clinical trial. These and other decisions toward a “more risk-balanced pipeline” are…
